FOR IMMEDIATE RELEASE
Monday, November 04, 2002
University of California Davis
Media Contacts:
Martha Alcott
(916) 734-9027
martha.alcott@udcmc.ucdavis.edu
Identifying Diagnostic Markers for Autism
In response to a 1999 groundbreaking study that found elevated peptides in
children with either autism or mental retardation, the UC Davis M.I.N.D.
Institute is launching the most comprehensive study of its kind to identify
diagnostic markers for children who are likely to develop autism.
"Being able to predict who might develop autism will have a enormous impact
on children with the neurodevelopmental disorder by allowing us to intervene
earlier with effective treatments or, hopefully, by preventing autism from
occurring," said David G. Amaral, research director of the UC Davis M.I.N.D.
Institute and principal investigator of the new study. "The 1999 study
proved to us that finding a biomarker is possible, and it is a top priority
for the M.I.N.D. Institute to identify it." To conduct this important
research, the M.I.N.D. Institute has entered into an initial agreement with
the Mountain View, Calif., company, SurroMed, Inc. to analyze clinical
samples from about 105 children -- about 70 with autism and the remainder
with typical development. Using SurroMed's advanced technologies for
profiling and analyzing thousands of immune cell populations, proteins and
low-molecular-weight organic molecules, such as sugars, peptides or lipids,
in small volumes of blood and/or other biological samples, SurroMed and the
M.I.N.D. Institute will be able to identify any unique properties present in
the blood chemistry of children with autism. The results of these studies
will be a major step toward the development of diagnostic tests.
"Although this is a relatively small study, it is the most comprehensive
analysis for biological markers of autism conducted to date, monitoring more
biological variables than ever before," Amaral said.
One of the first studies funded by the M.I.N.D. Institute looked at the
prevalence of eight peptides in blood spots collected from children at
birth. The research discovered that several of the peptides were elevated in
children who later became autistic or were mentally retarded, but not in
children with cerebral palsy or normal control children. This work,
conducted under the auspices of the California Birth Defects Monitoring
Program by a team of researchers that included physicians Karin Nelson at
the National Institutes of Health and Robin Hansen at the M.I.N.D.
Institute, led to optimism that a diagnostic marker for autism could be
identified using more sophisticated techniques.
"While their discovery was groundbreaking, the technology used in that study
was slow, making it difficult to replicate or broaden," Amaral said. "With
SurroMed's proprietary platform, we now have a technology that overcomes
those earlier constraints."
Results from this current study are expected by December 2003 and, if
promising, the M.I.N.D. Institute would enter into negotiations with
SurroMed to transfer the entire research platform to the institute to better
accommodate the analysis of larger numbers of children.
The UC Davis M.I.N.D. Institute in Sacramento, Calif., was founded in 1998
as a unique interdisciplinary organization of parents, community leaders,
researchers, clinicians and volunteers to study and treat autism, fragile X
syndrome, dyslexia, attention deficit disorder, Asperger's syndrome and
other neurodevelopmental disorders. More information about the institute is
available here.
Vaccination News Home Page
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.